ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2014
Familial colorectal cancer, beyond Lynch syndrome.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 86 citations in OpenAlex.
- Molecular markers associated with elevated colorectal cancer risk: a mini review.Hereditary cancer in clinical practice · 2025Review
- Natural product-based nanotechnological formulations for colorectal cancer treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Integrating next-generation sequencing and artificial intelligence for the identification and validation of pathogenic variants in colorectal cancer.Frontiers in oncology · 2025Article
- Genetics, diet, microbiota, and metabolome: partners in crime for colon carcinogenesis.Clinical and experimental medicine · 2024Review
- Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer.Biomarker research · 2024Review
- Molecular pathology of colorectal cancer: The Saudi situation in perspective.Saudi medical journal · 2023Review
- Germline gain-of-function MMP11 variant results in an aggressive form of colorectal cancer.International journal of cancer · 2023Article
- Recent advances in nanomedicine preparative methods and their therapeutic potential for colorectal cancer: a critical review.Frontiers in oncology · 2023Review
- LINC01614 Promotes Colorectal Cancer Cell Growth and Migration by Regulating miR-217-5p/HMGA1 Axis.Analytical cellular pathology (Amsterdam) · 2023Article
- Review
- Review
- Awareness, Knowledge, Perceptions, and Attitudes towards Familial and Inherited Cancer.Medicina (Kaunas, Lithuania) · 2022Article
- The role of gut microbiota in the development of colorectal cancer: a review.International journal of colorectal disease · 2022Review
- Evaluation of Classic, Attenuated, and Oligopolyposis of the Colon.Gastrointestinal endoscopy clinics of North America · 2022Review
- Natural Products from Actinobacteria as a Potential Source of New Therapies Against Colorectal Cancer: A Review.Frontiers in pharmacology · 2022Review
- Integrative Transcriptomic Network Analysis of Butyrate Treated Colorectal Cancer Cells.Cancers · 2021Article
- Prevalence and spectrum of germline cancer susceptibility gene variants and somatic second hits in colorectal cancer.American journal of cancer research · 2021Article
- The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance.International journal of molecular sciences · 2020Review
- Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers.Annual review of immunology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Although 30% of individuals diagnosed with colorectal cancer (CRC) report a family history of the disease, only 5% to 6% carry germline mutations in genes associated with known hereditary cancer syndromes. The evaluation and management of families affected with CRC can be complicated by variability in disease phenotypes and limited sensitivity of genetic tests. In this review, we examine what is currently known about familial CRC and what we have yet to learn, and explore how novel genomic approaches might be used to identify additional genetic and epigenetic factors implicated in heritable risk for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.